LAPROPHAN AND THE MAScIR FOUNDATION SIGNED A PARTNERSHIP AGREEMENT FOR SCIENTIFIC DEVELOPMENT IN THE PHARMACEUTICAL FIELD

The Laprophan Group and the MAScIR Foundation signed on Friday, March 4, 2022, a partnership agreement in the field of research, scientific and technological development. This 3-year partnership covers the terms and conditions of cooperation between the two institutions

Thus, Laprophan and the MAScIR Foundation have identified research and development projects that address public health issues. Implemented within the framework of specific agreements, these projects will mainly focus on the joint development of « point of care » diagnostic kits through relying on the expertise acquired by the Foundation’s medical biology department, notably in the development of diagnostic kits for cancer and infectious diseases.

Other research topics will also be the subject of cooperation, such as the development, exploitation and industrial synergy in the field of active pharmaceutical ingredients (APIs) and excipients, the development of synergies in biosimilars, monoclonal antibodies and analytical outsourcing.

On this occasion, Dr. Farid BENNIS, President and CEO of Laprophan Laboratories, welcomed the signing of this agreement with the MAScIR Foundation and renewed Laprophan’s commitment to research and development and innovation in order to best address the country’s health needs. For his part, Mr. Hicham EL HABTI, President of the MAScIR Foundation, welcomed the conclusion of this partnership and reaffirmed the vocation of the MAScIR Foundation for science, innovation and research and its willingness to respond to the current needs of the industrial fabric and Moroccan economic operators in order to promote the « Made in Morocco » brand.

 

About Laprophan

Pioneer of the pharmaceutical industry in Morocco, Laprophan is a Moroccan pharmaceutical company that has been operating in the drug industry since 1949. It has a long tradition of research and holds 5 marketed products, corresponding to 500 patents registered in over 100 countries.

Laprophan is a key player in the Moroccan healthcare sector with a broad portfolio of more than 400 drugs covering several therapeutic areas.